

Regimen Reference Order – CLL – fludarabine (IV)

ARIA: - CLL – [fludarabine (IV)]

Planned Course: Every 28 days for 6 cycles

Indication for Use: Chronic Lymphocytic Leukemia

CVAD: At Provider's Discretion

Proceed with treatment if:

- Creatinine clearance greater than 30 mL/minute

Cycle 1

- Proceed with treatment regardless of CBC

Cycle 2 onwards

- ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$
 - ❖ Contact Hematologist if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

| Drug | Dose | CCMB Administration Guideline |
|-------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| allopurinol | 300 mg | Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles (Self-administered at home) Only patients at risk of tumor lysis syndrome will be prescribed allopurinol |

Treatment Regimen – CLL – fludarabine (IV)

Establish primary solution 500 mL of: normal saline

| Drug | Dose | CCMB Administration Guideline |
|--------------------|----------------------|-------------------------------------------|
| Days 1 to 5 | | |
| fludarabine | 25 mg/m ² | IV in normal saline 50 mL over 30 minutes |

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

All Cycles

- CBC, serum creatinine, urea, liver enzymes, electrolytes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Recommended Support Medications

| Drug | Dose | CCMB Administration Guideline |
|-------------------------------|------------|--------------------------------------------------------|
| valACYclovir | 500 mg | Orally once daily |
| sulfamethoxazole-trimethoprim | 800/160 mg | Orally twice daily on Saturdays and Sundays ONLY |
| metoclopramide | 10 – 20 mg | Orally every 4 hours as needed for nausea and vomiting |

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- valACYclovir is prescribed for herpes zoster (shingles) prophylaxis
- sulfamethoxazole-trimethoprim DS is prescribed for *Pneumocystis jirovecii* pneumonia prophylaxis
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Patients on fludarabine should receive irradiated blood products
- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy **Hepatitis B Monitoring for Oncology and Hematology Patients** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- valACYclovir and sulfamethoxazole-trimethoprim DS continue while on treatment and for 6 months after discontinuation of fludarabine due to risk of prolonged immunosuppression